$ABBV News

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

AbbVie Won FDA Approval for At-Home Skyrizi Starts in Crohn’s. Here’s When It Should Show Up in Sales

AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?

AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease

BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?

Goldman Sachs Maintains Neutral on AbbVie, Raises Price Target to $294

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie’s skin disease drug posts Phase III win as market competition heats up

What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer

AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS Trial

AbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst

Jim Cramer and Ken Fisher Like This Healthcare Stock

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?

AbbVie Reports Topline Results From Phase 3 INTREPID Study Evaluating Lutikizumab, Investigational Dual-Variable-Domain IL 1α/1β Antagonist, In Hidradenitis Suppurativa; Study Met Primary Endpoint And 8 Ranked Secondary Endpoints

AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors

AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story?

AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?